bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress Read more about bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress
bluebird bio Enters Lentiviral Vector Patent License Agreement with GlaxoSmithKline for Commercialization of Gene Therapies Read more about bluebird bio Enters Lentiviral Vector Patent License Agreement with GlaxoSmithKline for Commercialization of Gene Therapies
bluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies Read more about bluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies
bluebird bio to Present at Upcoming Investor Conferences Read more about bluebird bio to Present at Upcoming Investor Conferences
bluebird bio Appoints New Senior Manufacturing and Corporate Development Executives Read more about bluebird bio Appoints New Senior Manufacturing and Corporate Development Executives
bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine Read more about bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine
bluebird bio to Present at Two Investor Conferences in March Read more about bluebird bio to Present at Two Investor Conferences in March
bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress Read more about bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress
bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease Read more about bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease
bluebird bio to Present at the 35th Annual J.P. Morgan Healthcare Conference Read more about bluebird bio to Present at the 35th Annual J.P. Morgan Healthcare Conference